Keytruda Injection contains Pembrolizumab, a monoclonal antibody that targets the programmed death receptor-1 (PD-1) on T-cells. It aids in regaining the immune system's capacity to identify and combat cancer cells by inhibiting PD-1.

Brand Name: Keytruda

Composition: Pembrolizumab

Mechanism of Action:

In order to suppress the immune response, pembrolizumab inhibits the PD-1 (programmed death-1) receptor, which often connects with PD-L1 and PD-L2 on tumor cells. Pembrolizumab reactivates T-cells by blocking PD-1, which makes it possible for them to recognize and combat cancer cells.

Uses:

• Non-Small Cell Lung Cancer
• Melanoma
• Head and Neck Squamous Cell Carcinoma
• Classical Hodgkin Lymphoma
• Urothelial Carcinoma
• Renal Cell Carcinoma
• Triple-Negative Breast Cancer
• Esophageal or Gastric Cancers

Dosage and Administration:

Obtainable as a solution or lyophilized powder. Intravenous infusion over a 30-minute period is the administration route.

Side Effects:

·         Hot flashes

·         Sweating

·         Decreased libido

·         Nausea

·         Vomiting

·         Mood changes

·         Bone pain

·         Weight gain

Safety Advise:

Kidney  

Please see your doctor before using Keytruda Injection if you have kidney condition. Before writing a prescription for you, your doctor will consider the advantages and any possible hazards.

Liver  

Please see your doctor before using Keytruda Injection if you have hepatic condition. Before writing a prescription for you, your doctor will consider the advantages and any possible hazards.

Pregnancy  

ecause of the possible risk to the fetus, it is contraindicated. Kindly speak with your Healthcare Professional.

Breast Feeding  

Not recommended for use in breastfeeding women. Kindly speak with your Healthcare Professional.

  Alcohol  

Drinking alcohol while taking Keytruda Injection is not advised. Kindly speak with your Healthcare Professional.

Storage:

Store at 2–8°C  in the original carton to protect from light.Do not freeze or shake

How to use this Medication?

A doctor or nurse at a hospital or medical facility will mix the powdered pembrolizumab injection with fluids and administer it intravenously (into a vein) during a 30-minute period. For as long as your doctor advises you to undergo treatment, it is typically injected once every three or six weeks.

Serious side effects could occur during or soon after the infusion of pembrolizumab injection. Inform your physician right once if you encounter any of the following symptoms: back pain, itching, rash, hives, fever, chills, shaking, lightheadedness, fainting, shortness of breath, or trouble breathing.

Disclaimer:

The main goal of Apothecare Wellness is to make sure that the information it provides to customers is correct, reliable, and reviewed by specialists. This website's contents and information are strictly for informational purposes. They are not meant to be used in place of expert medical advice, diagnosis, or care. Please consult your physician for guidance and ask any questions you may have about any condition or medication. If you read anything on Apothecare Wellness, do not discount or delay obtaining competent medical advice. Our goal is to enhance the doctor-patient relationship, not to take its place